Savolitinib
Savolitinib is a small molecule inhibitor that targets the MET tyrosine kinase receptor. It is an experimental drug being investigated for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and papillary renal cell carcinoma (PRCC). Savolitinib works by selectively inhibiting the activity of the MET receptor, which plays a crucial role in the development and progression of certain cancers through its involvement in processes such as cell growth, survival, angiogenesis, and metastasis.
Mechanism of Action[edit | edit source]
Savolitinib exerts its anti-cancer effects by specifically targeting and inhibiting the MET receptor tyrosine kinase. The MET receptor can be abnormally activated in some cancers due to genetic mutations, amplifications, or overexpression, leading to increased tumor growth and spread. By inhibiting this receptor, savolitinib disrupts these cancer-promoting signals, thereby inhibiting tumor growth and progression.
Clinical Trials[edit | edit source]
Savolitinib has been evaluated in several clinical trials for its efficacy and safety in treating various cancers. In NSCLC, it has been studied in patients with MET-driven tumors. For RCC and PRCC, trials have focused on its use as a monotherapy or in combination with other therapeutic agents. The outcomes of these trials have provided valuable insights into the potential therapeutic roles of savolitinib, although its efficacy and safety profiles are still under investigation.
Potential Indications[edit | edit source]
The primary potential indications for savolitinib include:
- Non-small cell lung cancer (NSCLC) with MET alterations
- Renal cell carcinoma (RCC)
- Papillary renal cell carcinoma (PRCC)
Safety and Side Effects[edit | edit source]
As with any investigational drug, understanding the safety profile and side effects of savolitinib is a critical aspect of its clinical development. Common side effects observed in clinical trials may include nausea, vomiting, fatigue, and edema. However, detailed safety information continues to evolve as more data from ongoing clinical trials become available.
Current Status[edit | edit source]
As of the last update, savolitinib remains in the clinical trial phase, with various studies ongoing to further evaluate its efficacy and safety in different cancer types. Its approval status may vary depending on the outcomes of these trials and regulatory review processes in different countries.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
